Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
15 09 2020
Historique:
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 15 5 2021
Statut: epublish

Résumé

Seasonal malaria chemoprevention (SMC), with sulphadoxine-pyrimethamine plus amodiaquine (SP+AQ) is effective but does not provide complete protection against clinical malaria. The RTS,S/AS01 This is an individually randomised, double-blind, placebo-controlled trial. 5920 children aged 5-17 months were enrolled in April 2017 in Mali and Burkina Faso. Children in group 1 received three priming doses of RTS,S/AS01 The protocol was approved by the national ethics committees of Mali and Burkina Faso and the London School of Hygiene and Tropical Medicine. The results will be presented to all stakeholders and published in open access journals. NCT03143218; Pre-results.

Identifiants

pubmed: 32933955
pii: bmjopen-2019-035433
doi: 10.1136/bmjopen-2019-035433
pmc: PMC7493088
doi:

Substances chimiques

Antimalarials 0
Malaria Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT03143218']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035433

Subventions

Organisme : Medical Research Council
ID : MR/P006876/1
Pays : United Kingdom
Organisme : Department of Health [UK]
Pays : International
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

PLoS Med. 2011 Feb 01;8(2):e1000408
pubmed: 21304925
mBio. 2016 Apr 26;7(2):e00514-16
pubmed: 27118593
Malar J. 2011 Aug 04;10:223
pubmed: 21816032
PLoS One. 2011 Feb 14;6(2):e16976
pubmed: 21340029
Lancet. 2001 Dec 8;358(9297):1927-34
pubmed: 11747915
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
PLoS Med. 2011 Feb 01;8(2):e1000407
pubmed: 21304923
JAMA. 2006 Mar 8;295(10):1152-60
pubmed: 16522836
N Engl J Med. 2015 Nov 19;373(21):2025-2037
pubmed: 26488565
Stat Med. 2014 Jun 15;33(13):2263-74
pubmed: 24449504
Glob Health Action. 2013 Sep 13;6:21518
pubmed: 24041439
Am J Epidemiol. 2015 Jun 15;181(12):1008-17
pubmed: 26022663
Hum Vaccin. 2010 Jan;6(1):90-6
pubmed: 19806009
N Engl J Med. 2019 Jun 06;380(23):2197-2206
pubmed: 30699301
PLoS One. 2016 Dec 8;11(12):e0168421
pubmed: 27930741

Auteurs

Daniel Chandramohan (D)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK Daniel.Chandramohan@lshtm.ac.uk.

Alassane Dicko (A)

Malaria Research and Training Center, Bamako, Mali.

Issaka Zongo (I)

Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

Issaka Sagara (I)

Malaria Research and Training Center, Bamako, Mali.

Matthew Cairns (M)

Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Irene Kuepfer (I)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Modibo Diarra (M)

Malaria Research and Training Center, Bamako, Mali.

Amadou Tapily (A)

Malaria Research and Training Center, Bamako, Mali.

Djibrilla Issiaka (D)

Malaria Research and Training Center, Bamako, Mali.

Koualy Sanogo (K)

Malaria Research and Training Center, Bamako, Mali.

Almahamoudou Mahamar (A)

Malaria Research and Training Center, Bamako, Mali.

Frederic Sompougdou (F)

Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

Serge Yerbanga (S)

Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

Ismaila Thera (I)

Malaria Research and Training Center, Bamako, Mali.

Paul Milligan (P)

Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Halidou Tinto (H)

Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

Opokua Ofori-Anyinam (O)

GlaxoSmithKline Biologicals SA, Wavre, Belgium.

Jean-Bosco Ouedraogo (JB)

Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.

B Greenwood (B)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH